Payment overview · 2025
General Payments
$398.36
18 reported records · 6 companies
Healthcare provider profile · identity verified
John Coleman, MD
Allopathic & Osteopathic Physicians|Internal Medicine · FOREST, MS · NPI 1063945475
Verified facts
What the public records show
CMS Open Payments records show John Coleman, MD received $398.36 in general payments during 2025 across 18 reported records.
Novo Nordisk Inc accounted for 36.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Ozempic, Rybelsus, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 171 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Symbicort by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 157 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $146.02 | 36.7% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $139.66 | 35.1% | 8 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $55.17 | 13.8% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $21.93 | 5.5% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $19.23 | 4.8% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $16.35 | 4.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $398.36 | 18 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $142.75 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $87.60 | 5 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $55.17 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $52.06 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $21.93 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $19.23 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $16.35 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $4.46 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 171 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 157 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 36 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
72 | 17 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
171 | 39 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
39 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
157 | 31 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
36 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 765 | 210 |
| Amlodipine Besylate | Amlodipine Besylate | 711 | 215 |
| Gabapentin | Gabapentin | 501 | 151 |
| Prednisone | Prednisone | 473 | 274 |
| Omeprazole | Omeprazole | 472 | 137 |
| Furosemide | Furosemide | 438 | 126 |
| Eliquis | Apixaban | 356 | 58 |
| Metformin Hcl | Metformin Hcl | 351 | 103 |
| Losartan Potassium | Losartan Potassium | 346 | 100 |
| Levothyroxine Sodium | Levothyroxine Sodium | 342 | 96 |
| Pantoprazole Sodium | Pantoprazole Sodium | 341 | 110 |
| Tamsulosin Hcl | Tamsulosin Hcl | 332 | 86 |
| Lisinopril | Lisinopril | 311 | 87 |
| Sertraline Hcl | Sertraline Hcl | 298 | 75 |
| Potassium Chloride | Potassium Chloride | 267 | 65 |
| Carvedilol | Carvedilol | 245 | 66 |
| Duloxetine Hcl | Duloxetine Hcl | 229 | 69 |
| Trazodone Hcl | Trazodone Hcl | 228 | 60 |
| Diclofenac Sodium | Diclofenac Sodium | 222 | 106 |
| Hydrochlorothiazide | Hydrochlorothiazide | 214 | 72 |
| Metoprolol Succinate | Metoprolol Succinate | 197 | 63 |
| Clopidogrel | Clopidogrel Bisulfate | 179 | 47 |
| Allopurinol | Allopurinol | 172 | 46 |
| Memantine Hcl | Memantine Hcl | 172 | 27 |
| Farxiga | Dapagliflozin Propanediol | 171 | 39 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 167 | 56 |
| Xarelto | Rivaroxaban | 163 | 18 |
| Meloxicam | Meloxicam | 160 | 55 |
| Mirtazapine | Mirtazapine | 160 | 43 |
| Ozempic | Semaglutide | 157 | 31 |
| Montelukast Sodium | Montelukast Sodium | 152 | 40 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 152 | 46 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 144 | 111 |
| Fluticasone Propionate | Fluticasone Propionate | 144 | 64 |
| Pravastatin Sodium | Pravastatin Sodium | 143 | 43 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 142 | 54 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 137 | 47 |
| Spironolactone | Spironolactone | 130 | 40 |
| Methocarbamol | Methocarbamol | 129 | 71 |
| Donepezil Hcl | Donepezil Hcl | 125 | 34 |
| Famotidine | Famotidine | 124 | 32 |
| Ropinirole Hcl | Ropinirole Hcl | 120 | 34 |
| Quetiapine Fumarate | Quetiapine Fumarate | 117 | 22 |
| Glimepiride | Glimepiride | 116 | 33 |
| Buspirone Hcl | Buspirone Hcl | 115 | 35 |
| Metoprolol Tartrate | Metoprolol Tartrate | 112 | 33 |
| Pioglitazone Hcl | Pioglitazone Hcl | 101 | 33 |
| Tramadol Hcl | Tramadol Hcl | 99 | 43 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 97 | 68 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 96 | 32 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 95 | 77 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 93 | 32 |
| Azithromycin | Azithromycin | 92 | 76 |
| Jardiance | Empagliflozin | 82 | 18 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 82 | 42 |
| Tizanidine Hcl | Tizanidine Hcl | 80 | 36 |
| Alprazolam | Alprazolam | 73 | 12 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 73 | 21 |
| Linzess | Linaclotide | 72 | 17 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 72 | 18 |
| Metformin Hcl Er | Metformin Hcl | 68 | 21 |
| Baclofen | Baclofen | 65 | 24 |
| Escitalopram Oxalate | Escitalopram Oxalate | 63 | 20 |
| Finasteride | Finasteride | 63 | 18 |
| Pregabalin | Pregabalin | 63 | 20 |
| Hydralazine Hcl | Hydralazine Hcl | 60 | 18 |
| Sucralfate | Sucralfate | 60 | 21 |
| Celecoxib | Celecoxib | 59 | 22 |
| Fluoxetine Hcl | Fluoxetine Hcl | 59 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 58 | 15 |
| Colchicine | Colchicine | 58 | 13 |
| Fluconazole | Fluconazole | 54 | 34 |
| Amiodarone Hcl | Amiodarone Hcl | 51 | 13 |
| Clonazepam | Clonazepam | 51 | 11 |
| Myrbetriq | Mirabegron | 51 | 14 |
| Januvia | Sitagliptin Phosphate | 50 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 50 | 22 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 49 | 13 |
| Meclizine Hcl | Meclizine Hcl | 49 | 30 |
| Zolpidem Tartrate | Zolpidem Tartrate | 49 | 18 |
| Levetiracetam | Levetiracetam | 48 | 18 |
| Levofloxacin | Levofloxacin | 46 | 34 |
| Novolog Flexpen | Insulin Aspart | 46 | 20 |
| Paroxetine Hcl | Paroxetine Hcl | 44 | 11 |
| Alendronate Sodium | Alendronate Sodium | 43 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 43 | 14 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 42 | 12 |
| Nystatin | Nystatin | 42 | 27 |
| Latanoprost | Latanoprost | 41 | 12 |
| Dicyclomine Hcl | Dicyclomine Hcl | 40 | 18 |
| Doxycycline Hyclate | Doxycycline Hyclate | 40 | 31 |
| Mupirocin | Mupirocin | 39 | 25 |
| Simvastatin | Simvastatin | 39 | 14 |
| Symbicort | Budesonide/Formoterol Fumarate | 39 | 12 |
| Olanzapine | Olanzapine | 38 | 12 |
| Amoxicillin | Amoxicillin | 37 | 29 |
| Breo Ellipta | Fluticasone/Vilanterol | 37 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 37 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 36 | suppressed |
| Diazepam | Diazepam | 36 | suppressed |
| Rybelsus | Semaglutide | 36 | 13 |
| Oxybutynin Chloride | Oxybutynin Chloride | 35 | 12 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 35 | 16 |
| Propranolol Hcl | Propranolol Hcl | 35 | 12 |
| Divalproex Sodium | Divalproex Sodium | 34 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 34 | 17 |
| Ondansetron Odt | Ondansetron | 34 | 20 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 33 | 11 |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 32 | 11 |
| Entresto | Sacubitril/Valsartan | 32 | 11 |
| Bupropion Xl | Bupropion Hcl | 31 | 16 |
| Cephalexin | Cephalexin | 31 | 25 |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 31 | 14 |
| Ondansetron Hcl | Ondansetron Hcl | 30 | 23 |
| Ventolin Hfa | Albuterol Sulfate | 30 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 29 | 29 |
| Clindamycin Hcl | Clindamycin Hcl | 29 | 25 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 29 | 15 |
| Ezetimibe | Ezetimibe | 29 | suppressed |
| Ibuprofen | Ibuprofen | 29 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 27 | 22 |
| Kerendia | Finerenone | 27 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 27 | suppressed |
| Lorazepam | Lorazepam | 26 | suppressed |
| Lubiprostone | Lubiprostone | 26 | suppressed |
| Praluent Pen | Alirocumab | 26 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 26 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 25 | suppressed |
| Digoxin | Digoxin | 25 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 24 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 24 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 24 | suppressed |
| Combigan | Brimonidine Tartrate/Timolol | 23 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 23 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 23 | suppressed |
| Topiramate | Topiramate | 23 | suppressed |
| Trulicity | Dulaglutide | 23 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 23 | suppressed |
| Chlorthalidone | Chlorthalidone | 22 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 22 | suppressed |
| Glipizide | Glipizide | 22 | suppressed |
| Nifedipine Er | Nifedipine | 22 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 22 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 21 | suppressed |
| Scopolamine | Scopolamine | 21 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 21 | suppressed |
| Valsartan | Valsartan | 21 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 20 | suppressed |
| Novolog | Insulin Aspart | 20 | suppressed |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 20 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 20 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 20 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Aripiprazole | Aripiprazole | 19 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 19 | suppressed |
| Lamotrigine | Lamotrigine | 19 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 19 | suppressed |
| Vraylar | Cariprazine Hcl | 19 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 18 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 18 | 11 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Calcium Acetate | Calcium Acetate | 17 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 17 | suppressed |
| Felodipine Er | Felodipine | 17 | suppressed |
| Lacosamide | Lacosamide | 17 | suppressed |
| Repatha Sureclick | Evolocumab | 17 | suppressed |
| Synthroid | Levothyroxine Sodium | 17 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 17 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 16 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 16 | suppressed |
| Ranolazine Er | Ranolazine | 16 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 16 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 15 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 15 | suppressed |
| Estradiol | Estradiol | 15 | suppressed |
| Kapspargo Sprinkle | Metoprolol Succinate | 15 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 15 | suppressed |
| Risperidone | Risperidone | 15 | suppressed |
| Torsemide | Torsemide | 15 | suppressed |
| Verapamil Er | Verapamil Hcl | 15 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 15 | suppressed |
| Ciclopirox | Ciclopirox | 14 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 14 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 14 | suppressed |
| Mounjaro | Tirzepatide | 14 | suppressed |
| Sprintec | Norgestimate-Ethinyl Estradiol | 14 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 14 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 13 | suppressed |
| Creon | Lipase/Protease/Amylase | 13 | suppressed |
| Haloperidol | Haloperidol | 13 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 13 | suppressed |
| Metronidazole | Metronidazole | 13 | 13 |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 12 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 12 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 12 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 12 | suppressed |
| Methylprednisolone | Methylprednisolone | 12 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 12 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 12 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 12 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 11 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 11 | 11 |
| Cinacalcet Hcl | Cinacalcet Hcl | 11 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 11 | suppressed |
| Metolazone | Metolazone | 11 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 11 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $398.36 · 18 records | Novo Nordisk Inc | AIRSUPRA, CAPLYTA, FARXIGA, FREESTYLE LIBRE 3, Ozempic, REXULTI, Rybelsus, VRAYLAR | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error